WO2012087255A3 - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques Download PDF

Info

Publication number
WO2012087255A3
WO2012087255A3 PCT/TR2011/000274 TR2011000274W WO2012087255A3 WO 2012087255 A3 WO2012087255 A3 WO 2012087255A3 TR 2011000274 W TR2011000274 W TR 2011000274W WO 2012087255 A3 WO2012087255 A3 WO 2012087255A3
Authority
WO
WIPO (PCT)
Prior art keywords
imatinib
pharmaceutical formulations
excipient
weight
range
Prior art date
Application number
PCT/TR2011/000274
Other languages
English (en)
Other versions
WO2012087255A2 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2012087255A2 publication Critical patent/WO2012087255A2/fr
Publication of WO2012087255A3 publication Critical patent/WO2012087255A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations d'imatinib renfermant un désintégrant pharmaceutiquement acceptable dans une proportion comprise entre 0,1 % et 5 % en poids et au moins un autre excipient.
PCT/TR2011/000274 2010-12-20 2011-12-19 Formulations pharmaceutiques WO2012087255A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/10618A TR201010618A2 (tr) 2010-12-20 2010-12-20 İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
TR2010/10618 2010-12-20

Publications (2)

Publication Number Publication Date
WO2012087255A2 WO2012087255A2 (fr) 2012-06-28
WO2012087255A3 true WO2012087255A3 (fr) 2012-08-16

Family

ID=45529174

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/TR2011/000275 WO2012087256A2 (fr) 2010-12-20 2011-12-19 Formulations de capsules pharmaceutiques
PCT/TR2011/000276 WO2012087257A2 (fr) 2010-12-20 2011-12-19 Forme galénique orale contenant de l'imatinib et production de ladite forme galénique orale
PCT/TR2011/000274 WO2012087255A2 (fr) 2010-12-20 2011-12-19 Formulations pharmaceutiques

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000275 WO2012087256A2 (fr) 2010-12-20 2011-12-19 Formulations de capsules pharmaceutiques
PCT/TR2011/000276 WO2012087257A2 (fr) 2010-12-20 2011-12-19 Forme galénique orale contenant de l'imatinib et production de ladite forme galénique orale

Country Status (2)

Country Link
TR (1) TR201010618A2 (fr)
WO (3) WO2012087256A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL394169A1 (pl) * 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
KR20140065862A (ko) * 2012-11-22 2014-05-30 에스케이케미칼주식회사 발포성 속붕해성 이매티닙 제제
GB201304699D0 (en) * 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
ES2683361T3 (es) * 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
EP3019159A4 (fr) * 2013-07-09 2017-01-18 Shilpa Medicare Limited Compositions pharmaceutiques orales comprenant du mésylate d'imatinib
TWI608849B (zh) * 2014-06-16 2017-12-21 國邑藥品科技股份有限公司 可調控釋放度之高載藥量之醫藥組合物及其製備方法
EP3257499A1 (fr) 2016-06-17 2017-12-20 Vipharm S.A. Procédé pour la préparation de capsules de méthanesulfonate d'imatinib
WO2019229648A1 (fr) * 2018-05-28 2019-12-05 Shivalik Rasayan Limited Compositions orales de mésylate d'imatinib

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275372A1 (en) * 2005-06-03 2006-12-07 Elan Pharma International Limited Nanoparticulate imatinib mesylate formulations
US20070036850A1 (en) * 2005-08-15 2007-02-15 Siegfried Generics International Ag Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
US20090221519A1 (en) * 1999-12-27 2009-09-03 Novartis Ag Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US20060223817A1 (en) 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
US20090324718A1 (en) * 2006-09-01 2009-12-31 Ilan Zalit Imatinib compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221519A1 (en) * 1999-12-27 2009-09-03 Novartis Ag Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound
US20060275372A1 (en) * 2005-06-03 2006-12-07 Elan Pharma International Limited Nanoparticulate imatinib mesylate formulations
US20070036850A1 (en) * 2005-08-15 2007-02-15 Siegfried Generics International Ag Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Stable Tablet Formulation containing more than 80% of Imatinib mesylate", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 19 February 2008 (2008-02-19), XP013123894, ISSN: 1533-0001 *

Also Published As

Publication number Publication date
TR201010618A2 (tr) 2012-07-23
WO2012087255A2 (fr) 2012-06-28
WO2012087256A3 (fr) 2012-09-27
WO2012087257A2 (fr) 2012-06-28
WO2012087256A2 (fr) 2012-06-28
WO2012087257A3 (fr) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2012087255A3 (fr) Formulations pharmaceutiques
EP3626253A3 (fr) Formulations stables de linaclotide
WO2011076749A3 (fr) Forme solide de dosage pharmaceutique
HK1152478A1 (en) Solid pharmaceutical formulations comprising bibw 2992
WO2014045162A8 (fr) Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués
WO2010000877A3 (fr) Formulation à base de bisabolol et de [6]-paradol produisant un effet apaisant sur les irritations
WO2010146179A3 (fr) Composition pharmaceutique solide comprenant du rivaroxaban
WO2012051559A3 (fr) Compositions et méthodes de traitement de l'hypertension artérielle pulmonaire
NI201100227A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica.
WO2012101653A3 (fr) Compositions pharmaceutiques de mémantine à libération modifiée
WO2013106068A3 (fr) Compositions thérapeutiques de préparations déterminées à base de plantes, et leurs utilisations
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2010049449A3 (fr) Nouveaux sels de sunitinib
EP2241310A3 (fr) Formulations à libération modifiée d'émoxypine
WO2013057741A3 (fr) Compositions pharmaceutiques d'acide ursodésoxycholique
WO2011064558A3 (fr) Composition pharmaceutique
WO2012085284A3 (fr) Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci
WO2011142731A3 (fr) Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
EP2196463A4 (fr) Procédé de préparation d'acide 5,6-diméthylxanthone-acétique, dérivés ainsi obtenus et formulations pharmaceutiques de ceux-ci
WO2010079433A3 (fr) Composition pharmaceutique qui comprend un inhibiteur de la dipeptidyl peptidase-iv
GB2495651B (en) A novel herbal formulation advocated for the prevention and management of coronary heart disease
WO2011156045A3 (fr) Formulation d'ezatiostat en comprimés
WO2010149794A3 (fr) Nouvelle composition pharmaceutique comprenant du poly(allylamine-co-n,n'-diallyl-1,3-diamino-2-hydroxypropane)
WO2011139253A3 (fr) Compositions pharmaceutiques comprenant du ceftibutène

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11811588

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11811588

Country of ref document: EP

Kind code of ref document: A2